Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00198315 · ClinicalTrials.gov registry record · Phase 3

Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcinoma

A Phase 3 study, sponsored by Inovio Pharmaceuticals.

Terminated
Registry status
Phase 3
Development phase
130
Enrollment target

NCT00198315 is a Phase 3 study that was terminated before completion, run by Inovio Pharmaceuticals. The registered enrollment target is 130 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00198315, a Phase 3 study, was terminated before completion, sponsored by Inovio Pharmaceuticals.

TERMINATED
Registry status
Phase 3
Development phase
130 participants
Enrollment target

Study Summary

The purpose of the study is to evaluate Medpulser electroporation (EPT) with bleomycin with regard to local tumor recurrence, disease-free survival, and overall survival rates versus surgery in recurrent or secondary primary squamous cell carcinoma (SCC) of the anterior oral cavity, soft palate, or tonsil.

Interventions

  • COMBINATION_PRODUCT Medpulser electroporation with Bleomycin
  • PROCEDURE Tumor surgical excision

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2004-06
Est. Completion 2007-06-01
Phase Phase 3

Sponsor

Inovio Pharmaceuticals

28 total trials

What the Registry Record Tells You About NCT00198315

The ClinicalTrials.gov registry entry for NCT00198315 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inovio Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Medpulser electroporation with Bleomycin is the first listed.

NCT00198315 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00198315 about?

NCT00198315 is a clinical study titled "Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcinoma". The purpose of the study is to evaluate Medpulser electroporation (EPT) with bleomycin with regard to local tumor recurrence, disease-free survival, and overall survival rates versus surgery in recurrent or secondary primary squamous cell carcinoma (SCC) of the anterior oral cavity, soft palate, or ...

What is the current status of trial NCT00198315?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 130 participants. The study started on 2004-06. Estimated completion is 2007-06-01.

What interventions are being tested in trial NCT00198315?

The interventions under investigation include: Medpulser electroporation with Bleomycin (COMBINATION_PRODUCT), Tumor surgical excision (PROCEDURE).

Who is sponsoring clinical trial NCT00198315?

This trial is sponsored by Inovio Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.